Targeted Breast Cancer Therapy

  • Ingrid Belac Lovasić
  • Franjo Lovasić
Part of the Europeanization and Globalization book series (EAG, volume 5)


Despite great advances in treatment, breast cancer is still the most common cause of death in cancer-treated women. From the results of numerous clinical studies and meta-analyses, the development of chemotherapy in the treatment of breast cancer has brought significant clinical benefit to survival, whether the treatment is adjuvant or the one of metastatic disease. The development of core oncology, translational and clinical research has led to a better understanding of the biology and immunology of tumors, the generation of new immunotherapeutic possibilities and their implementation in everyday clinical practice. For now, mostly monoclonal antibodies, primarily trastuzumab, are used in clinical practice, which is the gold standard for the treatment of HER-2 positive patients. Besides lapatinib, further development of this area has resulted in introducing pertuzumab, a monoclonal antibody directed against the second binding site of the HER-2 receptor, and trastuzumab-DM1, a true pathway for further development of immunotherapy, a cytostatic and antibody conjugate. Phase III clinical trials have confirmed the efficacy of pertuzumab and trastuzumab-DM1. The other direction the development of tumor immune therapy was based on was focusing on the infrastructure of the host, especially the blood vessels. For this purpose, a monoclonal antibody directed against the vascular endothelial growth factor (VEGF), bevacizumab, has been developed.


  1. Baselga J, Swan MS (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Canc 9(7):463–475. CrossRefGoogle Scholar
  2. Baselga J, Bradbury I, Eidtmann H et al (2012a) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640. CrossRefGoogle Scholar
  3. Baselga J, Cortes J, Kim SB et al (2012b) Pertuzumab plus trastuzumab docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. CrossRefGoogle Scholar
  4. Blackwell KL, Burstein HJ, Sledge GW (2009) Updated survival analysis of a randomized study of Lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 69(24 Suppl 3):Abstract 61.
  5. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy, for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286–4293. CrossRefGoogle Scholar
  6. Cobleigh MA, Vogel C, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648. CrossRefGoogle Scholar
  7. Cortes J, Baselga J, Im YH et al (2013) Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 24(10):2630–2635. CrossRefGoogle Scholar
  8. Di Cosimo S, Baselga J (2008) Targeted therapy in breast cancer: where are we now? Eur J Cancer 44(18):2781–2790. CrossRefGoogle Scholar
  9. Dieras V, Miles D, Verma S et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732–742. CrossRefGoogle Scholar
  10. Forbes JF, Kennedy J, Pienkowski T et al (2006) BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer(MBC): main time to progression (TTP) analysis J Clin Oncol 24(Suppl 18):A-LBA516, 7sGoogle Scholar
  11. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. CrossRefGoogle Scholar
  12. Gianni L, Eirmann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial). Lancet 375(9712):377–384CrossRefGoogle Scholar
  13. Gianni L, Romieu GH, Lichinitser M et al (2013) AVEREL: a randomized phase III trial evaluating Bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31(14):1719–1725. CrossRefGoogle Scholar
  14. Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubucun, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27(34):5685–5692CrossRefGoogle Scholar
  15. Kimberly L, Blackwell K, Miles D et al (2012) Primary results from EMILIA, a phase 3study of trastuzumab-emtansine (T-DM-1) vs capecitabine (X) and lapatinib (L) in HER2 positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30:18_suppl,LBA-LBA1. CrossRefGoogle Scholar
  16. Láng I, Bell R, Feng FY, Lopez RI et al (2014) Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the retreatment after herceptin adjuvant trial. Clin Oncol (R Coll Radiol) 26(2):81–89. CrossRefGoogle Scholar
  17. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive breast cancer administreted as firstline treatment: the M77001 study group. J Clin Oncol 23(19):4265–4274CrossRefGoogle Scholar
  18. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247. CrossRefGoogle Scholar
  19. Perez E, Suman V, Davidson N et al (2009) Results of chemotherapy alone with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2 positive adjuvant breast cancer trial. In: Program and abstracts of the 32nd Annual San Antonio Breast Cancer Symposium; December 9–13, San Antonio, Texas, Abstract 80Google Scholar
  20. Perez EA, Romond EH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/witouth trastuzumab in patients with HER-2 breast cancer (abstract). J Clin Oncol 25(18):Abstract 512.
  21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRefGoogle Scholar
  22. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomised phase III study of trastuzumab, paclitaksel, and carboplatin compared with trastuzumab and palitaksel in women with HER-2 overexpressing metastatis breast cancer. J Clin Oncol 24(18):2786–2792CrossRefGoogle Scholar
  23. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260. CrossRefGoogle Scholar
  24. Schneider BP, Sledge GW Jr (2011) Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J Clin Oncol 29(18):2444–2447. CrossRefGoogle Scholar
  25. Slamon D, Eiermann W, Robert N et al (2009) Phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: BCIRG 006 study. In: Third Planned Efficacy Analysis. Program and abstracts of the 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, San Antonio, Texas, Abstract 62Google Scholar
  26. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 344(11):783–792CrossRefGoogle Scholar
  27. Spielmann M, Roche H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134CrossRefGoogle Scholar
  28. Swain SM, Ewer MS, Cortes J et al (2013a) Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18(3):257–264. CrossRefGoogle Scholar
  29. Swain SM, Sung-Bae K, Cortes J et al (2013b) Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study. Lancet Oncol 14(6):461–471. CrossRefGoogle Scholar
  30. Untch M, Rezai M, Loibl S et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQUattro study. J Clin Oncol 28(12):2024–2031CrossRefGoogle Scholar
  31. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumag as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726. CrossRefGoogle Scholar
  32. von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27(12):1999–2006. CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ingrid Belac Lovasić
    • 1
  • Franjo Lovasić
    • 1
  1. 1.Clinic for Radiotherapy and OncologyUniversity Hospital Center RijekaRijekaCroatia

Personalised recommendations